Virax Biolabs Group Ltd (VRAX) Form 424B5 — Sep 4, 2026
Virax Biolabs filed a prospectus supplement on September 4, 2026 that refreshes its at-the-market offering program with H.C. Wainwright, restoring capacity to sell up to $2,070,060.20 of ordinary shares under its Form F-3 registration statement. The refresh was triggered by baby-shelf limits under General Instruction I.B.5 of Form F-3: the company has already sold approximately $3,658,152 through the ATM to date and $737,000 in the past 12 months, and its I.B.5-eligible capacity is capped by an $8,421,181 public float.
Key figures
- Gross Proceeds
- Up to $2,070,060.20 (new ATM capacity)
- Public Float Usd
- 8421181
- Last Closing Price
- 2.56
- Par Value Per Share
- 0.025
- Prior Atm Sales Usd
- 3658152
- Non Affiliate Shares
- 1324085
- Float Calculation Price
- 6.36
- Ib5 Sales Last12 Months Usd
- 737000
Price after filing
Close on the filing date to close N calendar days later (from $2.63). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.